FDOPA PET imaging in metabolically-active regions of treatment-naïve diffuse gliomas


  • 3,4-dihydroxy-6-[18F]-fluoro-l-phenylalanine (FDOPA) positron emission tomography (PET) imaging may help identify unbiased physiological features of metabolically-active gliomas and detect differences between molecular status and tumor grade.

Why this matters

    The identification of molecular subtype or tumor grade by FDOPA PET within metabolically-active regions of gliomas may help monitor treatment-related changes and predict prognosis.